The latest update is out from G1 Therapeutics (GTHX).
G1 Therapeutics, Inc. announced disappointing results for their Phase 3 trial, PRESERVE 2, which tested trilaciclib with chemotherapy agents in treating metastatic triple negative breast cancer. The trial failed to meet the primary goal of improving overall survival, a significant setback for the company’s leading drug candidate. This news is likely to impact investor confidence and the company’s stock value.
For an in-depth examination of GTHX stock, go to TipRanks’ Stock Analysis page.
